Hospira Snaps Up Biosimilar Product As Teva Restructures

Global specialty pharmaceutical company Hospira has acquired the global rights to Teva Pharmaceutical Industries' biosimilar filgrastim, expanding its presence in the potentially lucrative market for biopharmaceuticals. The purchase sees Hospira gain the rights to the biosimilar product, which was being developed as part of a strategic collaboration with Pliva/Barr Pharmaceuticals (now owned by Teva). Applications for marketing authorisation for the biosimilar were filed in the EU and Australia in Q109. As part of the agreement, Hospira has also acquired process development capabilities and a manufacturing plant in Croatia with the capacity to meet global filgrastim production, as well as future

To read the full article, please sign in or take a free trial.